- Home
- QNTM vs SCLX Comparison
QNTM vs SCLX Comparison
Compare QNTM & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNTM
- SCLX
- Stock Information
- Founded
- QNTM 1998
- SCLX 2011
- Country
- QNTM Canada
- SCLX United States
- Employees
- QNTM N/A
- SCLX N/A
- Industry
- QNTM
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- QNTM
- SCLX Health Care
- Exchange
- QNTM NYSE
- SCLX Nasdaq
- Market Cap
- QNTM 35.6M
- SCLX 33.9M
- IPO Year
- QNTM N/A
- SCLX N/A
- Fundamental
- Price
- QNTM $21.02
- SCLX $5.38
- Analyst Decision
- QNTM
- SCLX Strong Buy
- Analyst Count
- QNTM 0
- SCLX 3
- Target Price
- QNTM N/A
- SCLX $367.50
- AVG Volume (30 Days)
- QNTM 414.2K
- SCLX 132.9K
- Earning Date
- QNTM 08-13-2025
- SCLX 08-12-2025
- Dividend Yield
- QNTM N/A
- SCLX N/A
- EPS Growth
- QNTM N/A
- SCLX N/A
- EPS
- QNTM N/A
- SCLX N/A
- Revenue
- QNTM N/A
- SCLX $50,710,000.00
- Revenue This Year
- QNTM N/A
- SCLX $107.00
- Revenue Next Year
- QNTM N/A
- SCLX $82.52
- P/E Ratio
- QNTM N/A
- SCLX N/A
- Revenue Growth
- QNTM N/A
- SCLX 7.79
- 52 Week Low
- QNTM $2.70
- SCLX $3.60
- 52 Week High
- QNTM $38.25
- SCLX $78.05
- Technical
- Relative Strength Index (RSI)
- QNTM 54.17
- SCLX 50.63
- Support Level
- QNTM $20.89
- SCLX $4.53
- Resistance Level
- QNTM $38.25
- SCLX $5.60
- Average True Range (ATR)
- QNTM 4.22
- SCLX 0.41
- MACD
- QNTM 0.15
- SCLX 0.01
- Stochastic Oscillator
- QNTM 34.92
- SCLX 34.45
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.